全文获取类型
收费全文 | 60724篇 |
免费 | 6155篇 |
国内免费 | 1305篇 |
专业分类
耳鼻咽喉 | 516篇 |
儿科学 | 1345篇 |
妇产科学 | 1647篇 |
基础医学 | 5115篇 |
口腔科学 | 1366篇 |
临床医学 | 5715篇 |
内科学 | 9437篇 |
皮肤病学 | 439篇 |
神经病学 | 2413篇 |
特种医学 | 1915篇 |
外国民族医学 | 25篇 |
外科学 | 7391篇 |
综合类 | 7833篇 |
现状与发展 | 4篇 |
预防医学 | 7809篇 |
眼科学 | 427篇 |
药学 | 5285篇 |
101篇 | |
中国医学 | 1863篇 |
肿瘤学 | 7538篇 |
出版年
2024年 | 117篇 |
2023年 | 1072篇 |
2022年 | 1805篇 |
2021年 | 2892篇 |
2020年 | 2725篇 |
2019年 | 2481篇 |
2018年 | 2488篇 |
2017年 | 2349篇 |
2016年 | 2344篇 |
2015年 | 2455篇 |
2014年 | 4242篇 |
2013年 | 4319篇 |
2012年 | 3610篇 |
2011年 | 3797篇 |
2010年 | 2859篇 |
2009年 | 2729篇 |
2008年 | 2779篇 |
2007年 | 2769篇 |
2006年 | 2263篇 |
2005年 | 2035篇 |
2004年 | 1808篇 |
2003年 | 1509篇 |
2002年 | 1337篇 |
2001年 | 1135篇 |
2000年 | 1005篇 |
1999年 | 927篇 |
1998年 | 782篇 |
1997年 | 776篇 |
1996年 | 701篇 |
1995年 | 595篇 |
1994年 | 589篇 |
1993年 | 442篇 |
1992年 | 467篇 |
1991年 | 426篇 |
1990年 | 354篇 |
1989年 | 337篇 |
1988年 | 308篇 |
1987年 | 247篇 |
1986年 | 235篇 |
1985年 | 291篇 |
1984年 | 253篇 |
1983年 | 166篇 |
1982年 | 209篇 |
1981年 | 181篇 |
1980年 | 166篇 |
1979年 | 145篇 |
1978年 | 112篇 |
1977年 | 100篇 |
1976年 | 95篇 |
1975年 | 94篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
81.
Palat Balachandran M.S. M.Ch. Shaleen Agarwal M.S. M.Ch. Narendra Krishnani M.D. Chandra M. Pandey Ph.D. Ashok Kumar M.S. M.Ch. Sadiq S. Sikora M.S. Rajan Saxena M.S. Vinay K. Kapoor M.S. 《Journal of gastrointestinal surgery》2006,10(6):848-854
The aim of this study was to examine the predictors of long-term survival (>24 months) in patients with gall bladder cancer.
A retrospective review of 117 cases of gall bladder cancer resected between 1989 and 2000. The resections included 80 simple
cholecystectomies and 37 extended procedures. Patients with survival >24 months (n=44) were compared with those having survival
<24 months (n=73) for 17 prognostic factors. Overall median survival was 16 months with a 5-year survival of 27%. T status
(P=.000) and adjuvant chemoradiotherapy (P=.001) were independent predictors of long-term survival. Survival advantage was
seen in T3N+ve disease (P=.007) with extended procedures. Complete (R0) resection was attained in 30 patients with a 5-year
survival advantage of 30% as compared with incomplete (R1) resection (P=.0002). Adjuvant chemoradiotherapy improved survival
in simple cholecystectomy group (P=.0008) but no advantage was seen after extended procedures. Stage III (P=.001) and node-positive
disease (P=.0005) had significant benefit with adjuvant therapy. Poor differentiation and vascular invasion were associated
with poor long-term survival. R0 resection was associated with prolonged survival. Extended procedures improved survival in
patients with T3N+ve disease. Addition of chemoradiotherapy made significant improvement in long-term survival in stage III
and node-positive lesions and in patients undergoing simple cholecystectomy. R0 resection predicted long-term survival in
gall bladder cancer. T3 N+ve disease had better survival after extended procedures. Adjuvant chemoradiotherapy improved survival
in stage III and node-positive disease. Poor differentiation and vascular invasion were adverse predictors of survival. 相似文献
82.
83.
目的通过2004年和2005年本校女教职工妇科查体结果的分析,发现女教职工中未被识别的疾病与致病因子,从而达到防病、治病的目的。通过两年查体结果的分析比较,进一步说明高校女教职工定期进行妇科查体的必要性。方法收集、整理2004年和2005年两年的妇科查体结果,并对不同年龄组的患病率进行分析、比较,查找原因。结果两年的查体结果表明,2005年各年龄段妇科疾病的发病率明显较2004年低,经卡方比较,差异有显著性。结论对女教职工实施定期的妇科查体,对及旱发现妇科疾病、及时进行适当的治疗、保障女教职工的身体健康起了重要作用。 相似文献
84.
85.
86.
申秀敏 《中国医学检验杂志》2006,7(6):420-421
[目的]探讨各型肝炎的感染率。[方法]研究对象为我院住院及门诊患者,共计4110例。采用微粒子酶免分析法(MEIA)及酶联免疫吸附法(ELISA)进行肝炎分型(甲、乙、丙、丁、戊、庚肝)检测。[结果]4110例受检者中,单纯乙肝感染者133例,占3.24%;单纯丙肝感染者134例,占3.26%;单纯戊肝感染者2例,占0.05%;乙肝合并丙肝感染者3例,占0.07%;丙肝合并戊肝感染者1例,占0.02%;HAV、HDV、HGV无一例感染,感染率为0。另外,男性受检者2088人,乙肝感染者88人,占4.21%;丙肝感染者48人,占2.30%;女性受检者2022人,乙肝感染45人,占2.23%;丙肝感染86人,占4.25%。[结论]除丙肝外,各型感染率均低于全国平均感染率,与相关资料报道相差甚远。乙肝及丙肝仍以单纯感染多见。另,本组资料还显示,男性较女性更易感染乙肝病毒,而女性感染丙肝者远远高于男性,对于丙肝感染的性别差异,尚无报道,需进一步探讨。 相似文献
87.
88.
89.
AIMS: To establish all-cause and cause-specific death rates, and risk factors for mortality in insulin-treated diabetic individuals living in the province of Canterbury, New Zealand. METHODS: Insulin-treated diabetic subjects (n = 995) on the Canterbury Diabetes Registry were followed up over 15 years and vital status determined. Death rates were standardized and hazard regression was used to model the effects of demographic covariates on relative survival time. RESULTS: There were 419 deaths in 11 226.3 person-years of follow-up with a standardized mortality ratio (SMR) of 2.0 (95% confidence interval (CI) 1.8-2.2). Relative mortality was greatest for the group aged 0-29 years (SMR 3.0 (95% CI 2.4-3.7)). After controlling for diabetes duration and gender, a 10-year increment in age of onset was associated with a 33% decrease in relative hazard (95% CI 29-36%), indicating that excess mortality due to diabetes declines with rising age of onset. After controlling for age of onset and gender, each 10-year increment in duration of diabetes is associated with a 26% decrease in relative hazard (95% CI 24-29%), indicating that with longer survival the mortality hazard approaches the general population hazard. Relative mortalities were increased for cardiovascular, renal and respiratory disease, but not malignancy. Relative mortality from acute metabolic complications was increased in the subgroup with age of onset of diabetes < 30 years and requiring insulin within 1 year of diagnosis. CONCLUSIONS: Mortality rates are high for insulin-treated diabetic individuals relative to the general population. 相似文献
90.
R. H. Wiesner B. J. Steffen K. M. David A. H. Chu R. D. Gordon J. R. Lake 《American journal of transplantation》2006,6(7):1609-1616
Mycophenolate mofetil (MMF) used in a triple-drug regimen has been shown to decrease acute rejection rates, compared to a double-drug regimen. The impact of MMF on late acute rejection (LAR) episodes has not been well described. To investigate the risk of LAR (rejection > or = 6 months post-transplantation) data from the Scientific Registry of Transplant Recipients (SRTR) were used. We studied adult primary liver transplant recipients transplanted between June 1, 1995, and April 30, 2004, with hepatitis C virus (HCV) (n = 3356), hepatitis B virus (HBV) (n = 550) or a nonviral (n = 5740) primary cause of liver disease who were recorded as receiving continuous 3-(MMF + Tacro + steroids) versus 2-drug (Tacro + steroids) therapy for at least 6 months immediately post transplantation. Kaplan-Meier analysis showed significantly lower LAR rates 4 years post-transplant in 3- versus 2-drug HCV, HBV and nonviral disease patients. Multivariate regression confirmed 3- versus 2-drug therapy to be associated with a decreased risk of LAR. Late graft survival was significantly lower at 4 years post-transplant for patients with LAR 6-12 months post-transplantation versus patients with early rejection (78.0% vs. 87.0%, p < 0.001) and no rejection (88.1%, p < 0.001). Three-drug versus 2-drug therapy for a minimum of 6 months may offer a better treatment strategy to avoid the consequences and expense of LAR episodes. 相似文献